Article thumbnail

Can vaccinia virus be replaced by MVA virus for testing virucidal activity of chemical disinfectants?

By Holger F Rabenau, Ingrid Rapp and Jochen Steinmann
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2908096
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2004). Anonymous: Prüfung und Deklaration der Wirksamkeit von Desinfektionsmitteln gegen Viren. Stellungnahme des Arbeitskreises Viruzidie beim Robert Koch-Institut (RKI) sowie des Fachausschusses Virusdesinfektion der
  2. (2000). Anonymous: Richtlinien zur Prüfung chemischer Desinfektionsmittel für die Veterinärmedizin. Deutsche Veterinärmedizinische Gesellschaft e. V.,
  3. (1980). Arita I: The confirmation and maintenance of smallpox eradication.
  4. (1931). Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Path Pharmako
  5. (2003). Belshe RB: Stability of undiluted and diluted vaccinia-virus vaccine,
  6. (2004). CC: Ocular vaccinia infection in laboratory worker,
  7. (2005). CDC: Laboratory-acquired vaccinia exposures and infections---United States,
  8. CDC: Recommendations for using smallpox vaccine in a pre-event vaccination program: supplemental recommendations of the Advisory
  9. (1972). CDC: Supplement: collected recommendations of the Public Health Service Advisory Committee on Immunization Practices. MMWR
  10. (2006). CDC: Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR
  11. Chemical disinfectants and antiseptics. Virucidal quantitative suspension test for chemical disinfectants and antiseptics used in human medicine. Test method and requirements (phase 2, step 1).
  12. (2005). E: Reactions to small pox vaccine in naïve and previously-vaccinated individuals. Vaccine
  13. (2002). Expected adverse events in a mass smallpox vaccination campaign. Effect Clin Pract
  14. (1979). Finke H: A contribution to the stability of the MVA-vaccine. ZBL Bakt Hyg I Abt Orig
  15. (2005). Grabenstein JD: Comparison of clinical presentation of acute myocarditis following smallpox vaccination to acute coronary syndromes in patients <40 years of age.
  16. (2001). Hanlon CA: Human infection due to recombinant vaccinia-rabies glycoprotein virus.
  17. (2005). IK: Stability of diluted smallpox vaccine under simulated clinical conditions. Vaccine
  18. (2004). JL: Laboratory-acquired vaccinia infection.
  19. (2002). JM: Neurologic adverse events associated with smallpox vaccination in the United States,
  20. (2003). Laboratory acquired infection with recombinant vaccinia virus containing an immunomodulating construct.
  21. (2001). Osterhaus AD: Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine
  22. (1991). Record FM: Accidental infection of laboratory worker with recombinant vaccinia virus. Lancet
  23. (2005). The future of smallpox vaccination: is MVA the key? Med Immunol
  24. (1908). The method of &quot;right and wrong cases&quot; (&quot;constant stimuli&quot;) without Gauss's formulae.
  25. (1978). The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zbl Bakt Hyg I Abt Orig B
  26. (2008). Truyen U: Substitution of vaccinia virus Elstree by modified vaccinia virus Ankara to test the virucidal efficacy of chemical disinfectants. Zoonoses Public Health
  27. (2008). Vaccinia Virus Infection -